ClinicalTrials.gg
RecruitingNCT06449664ADT-trainUpdated Jun 10, 2024

Training for Men Undergoing Androgen Deprivation Therapy.

An interventional study of ADT-train in Prostate Cancer, sponsored by The Swedish School of Sport and Health Sciences. Recruiting at 1 site in Sweden. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-10.

Sponsored by The Swedish School of Sport and Health Sciences · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Prostatic Neoplasms with a site in Sweden — 35 open to participants now, 57 under way, 22 of them phase 3. Prostatic Neoplasms · Sweden.

Planned enrollment
114th of 128
60 · median 462
Started
2024
with 12 others
No phase
29 of 153
12 open now
Primary completion
2026-12
later than 18 of 56 live
Registered
133rd of 153
by date

Among the 153 studies in Prostatic Neoplasms with a site in Sweden, this one is the 114th largest by planned enrollment of the 128 interventional ones that give a count, is one of 13 that started in 2024, is one of 29 with no phase, reaches primary completion later than 18 of the 56 other live ones, and was the 133rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

35 of the 153 studies in Prostatic Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 50 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Prostatic Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effects of a newly developed training concept on men with prostate cancer undergoing androgen deprivation therapy (ADT).

The main questions it aims to answer are:

  • How feasible and safe is the new training concept?
  • How efficient is the training concept to counteract side effects caused by ADT?

Researchers will compare the new training concept with usual care to evaluate how efficient the training concept is to counteract the ADT-related side effects.

Participants in the intervention group will perform the new training concept twice weekly for 12 weeks. Participants in the control group will only receive usual care. All participants will visit the laboratory at baseline and after 6 and 12 weeks to measure the primary and secondary outcomes.

Read the detailed description

Detailed description of the training concept applied in the intervention:

The two weekly training sessions will be separated by at least two days and supervised by appropriately trained exercise professionals at The Swedish School of Sport and Health Sciences. The training includes a 10 min warm-up followed by 3-4 sets of 8 maximal repetitions on the flywheel machine followed by 16-24, 20 s intervals on a Monark cycle ergometer. The intervals will be performed as 3 blocks with the intention to execute 8 intervals in each block. When a participant manages to perform all 3 blocks with 8 intervals in each block (a total of 24 intervals) the resistance will be increased by \~20 W. The rest period between the intervals will be set to 10 s and the rest between the blocks to 2 min. The starting workload of the intervals will be individually adjusted to \~115 % of the participant's power output at VO2peak. The total duration of a training session will be 30-40 min (including worm-up).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Androgen deprivation therapy (ADT)
  • Flywheel training
  • High intensity training (HIT)
  • Resistance training
  • Aerobic training
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed
  2. confirmed localised or locally advanced prostate cancer
  3. planned radiotherapy in combination with ADT for at least six months (unfavorable intermediate risk and high-risk prostate cancer) with curative intent and with no known .

Exclusion criteria

Exclusion Criteria:

  1. very high risk localised prostate cancer planned for radiotherapy and ADT plus abiraterone and cortisone
  2. localized prostate cancer planned for radiotherapy without ADT
  3. on-going or previously treated with ADT or other hormonal treatments
  4. have any to physical testing/exercise as per the ACSM guidelines
  5. unable to comply with study procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Exercise

    The participants will exercise twice weekly performing the newly developed training concept including flywheel resistance training followed by aerobic cycling intervals.

    Behavioral: ADT-train

  • No intervention
    Control group

    The participants will receive usual care only.

Interventions

  • BehavioralADT-train

    A new training concept is tested on men with prostate cancer receiving androgen deprivation therapy

06

What researchers measure

Primary outcomes

  1. Aerobic fitness

    VO2peak (ml/kg/min); incremental ramp test on a cycle ergometer

    Time frame: Baseline and after 6 and 12 weeks

  2. Maximal leg strength

    Isometric squat test (N) measured on force plates

    Time frame: Baseline and after 6 and 12 weeks

Secondary outcomes

  1. Body fat

    Assessed by dual-energy x-ray absorptiometry (DEXA) (kg)

    Time frame: Baseline and after 6 and 12 weeks

  2. Lean body mass

    Assessed by dual-energy x-ray absorptiometry (DEXA) (kg)

    Time frame: Baseline and after 6 and 12 weeks

  3. Bone mineral density

    Assessed by dual-energy x-ray absorptiometry (DEXA) (g/cm2)

    Time frame: Baseline and after 6 and 12 weeks

  4. Quadriceps cross-sectional area

    Assessed by ultrasound (mm)

    Time frame: Baseline and after 6 and 12 weeks

  5. Static balance

    One leg balance test on the right and the left foot. Time to first footing is measured and the number of footings during 60s.

    Time frame: Baseline and after 6 and 12 weeks

  6. Walk capacity

    Usual and fast pace 6m walk test (s)

    Time frame: Baseline and after 6 and 12 weeks

  7. Lower body muscular endurance

    30 s chair stand test. Maximal number of sit-to-stand repetitions during 30 s.

    Time frame: Baseline and after 6 and 12 weeks

  8. Blood pressure

    Assessed by an automated blood pressure monitor (mmHg).

    Time frame: Baseline and after 6 and 12 weeks

  9. Whole body glucose uptake

    Assessed by an oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood glucose levels will be monitored throughout a period of 2 hours (mmol/L).

    Time frame: Baseline and after 6 and 12 weeks

  10. Whole body insulin response

    Assessed by an oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood insulin levels will be monitored throughout a period of 2 hours (μU/mL).

    Time frame: Baseline and after 6 and 12 weeks

  11. Blood biomarkers related to cardiovascular disease.

    Assessed by high-multiplex immunoassays quantifying proteins associated with biological functions linked to cardiovascular diseases. Approximately 100 proteins will be assessed. Examples of proteins are: C-Reactive Protein (CRP), Tissue Factor (F3), and Thrombomodulin (THBD).

    Time frame: Baseline and after 6 and 12 weeks

  12. Muscle fiber cross-sectional area (CSA)

    Type I and type II muscle CSA will be assessed by immunohistochemistry (µm2).

    Time frame: Baseline and after 12 weeks

  13. Muscle fiber distribution

    Type I and type II muscle fiber distribution will be assessed by immunohistochemistry (%).

    Time frame: Baseline and after 12 weeks

  14. Capillary content

    The number of capillaries per muscle fiber will be assessed by immunohistochemistry.

    Time frame: Baseline and after 12 weeks

  15. Myonuclei content

    The number of myonuclei per muscle fiber CSA will be assessed by immunohistochemistry.

    Time frame: Baseline and after 12 weeks

  16. Satellite cell content

    The number of satellite cells per muscle fiber CSA will be assessed by immunohistochemistry.

    Time frame: Baseline and after 12 weeks

  17. Mitochondrial content

    Mitochondrial content will be assessed by measuring citrate synthase activity in homogenized muscle samples (mmol/kg/dw/min).

    Time frame: Baseline and after 12 weeks

  18. Mitochondrial respiration

    Mitochondrial respiration will be assessed by respirometry of permeabilized muscle fibers (respiration ratio).

    Time frame: Baseline and after 12 weeks

  19. Genome-wide DNA methylation

    Assessed by Illumina EPIC arrays to identify epigenetically regulated genes and pathways associated with exercise and the ADT-treatment.

    Time frame: Baseline and after 12 weeks

  20. Transcriptome-wide RNA expression

    Assessed by RNA-sequencing to identify differently regulated genes and pathways associated with exercise and the ADT-treatment.

    Time frame: Baseline and after 12 weeks

  21. Protein expression

    Assessed by Western Blot and ELISA (AU). This could for example be proteins related to genes identified by the genome-wide DNA methylation analysis or transcriptome-wide RNA expression analysis.

    Time frame: Baseline and after 12 weeks

  22. Gene expression

    Assessed by quantitative real-time PCR (AU). This could for example be genes identified by the genome-wide DNA methylation analysis or transcriptome-wide RNA expression analysis.

    Time frame: Baseline and after 12 weeks

  23. Cancer treatment-related symptoms

    Assessed by the National Prostate Cancer Register (NPCR) form. Scores scaled from 0 to 7. A higher score indicates more severe symptoms.

    Time frame: Baseline and after 6 and 12 weeks

  24. Physical activity

    Assessed by the physical activity questionnaire. Scores scaled from 1 to 8. A higher score indicates a more physically active participant.

    Time frame: Baseline and after 6 and 12 weeks

  25. Physical and psychological health

    Assessed by the Short Form Health Survey (SF-36). Scores scaled from 1 to 6. A higher score indicates better physical and psychological health.

    Time frame: Baseline and after 6 and 12 weeks

  26. Anxiety and depression

    Assessed by the Hospital Anxiety and Depression Scale (HADS). Scores scaled from 0 to 3. A higher score indicates more anxiety and depression.

    Time frame: Baseline and after 6 and 12 weeks

  27. Cancer and treatment-related fatigue

    Assessed by the Multidimensional Fatigue Inventory survey (MFI-20). Scores scaled from 1 to 5. A higher score indicates more fatigue.

    Time frame: Baseline and after 6 and 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 31 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Jun 10, 2024
StartActual
May 1, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 20, 2028
Last update
Jun 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06449664
Lead sponsor
The Swedish School of Sport and Health Sciences
Collaborators
Norwegian School of Sport Sciences, Karolinska Institutet, Prostate Cancer Foundation, Sahlgrenska University Hospital
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
May 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 20, 2028 (estimated)
Last update
Jun 10, 2024

Study contacts

Niklas Psilander, PhD
Contact
niklas.psilander@gih.se
+46 8 120 538 23

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion